Andexanet Alfa for Reversal of Factor Xa Inhibitors in Traumatic Brain Injury: A Retrospective Single-Centre Study | MicrobiomeTrials← Back to trialsNCT07898982
Andexanet Alfa for Reversal of Factor Xa Inhibitors in Traumatic Brain Injury: A Retrospective Single-Centre Study
CompletedOBSERVATIONAL
Trial Details
Start: 2024-08-01Est. Completion: 2026-08-01
Enrollment target: 34 participants Locations- University Medical Centre Ljubljana, Ljubljana, Slovenia
Other microbiome trials you might be interested in
Traumatic Brain Injury (TBI) Patients
Beta-blockers have shown promise as a treatment to improve patient prognosis following traumatic brain injury (TBI), alt…
Palma de Mallorca, SpainEst. completion Jun 1, 2028
Concussion (Diagnosis)Gait Abnormality
Approximately 1.6 to 3.8 million mild traumatic brain injuries, or concussions, occur yearly in the United States. Altho…
DeKalb, United StatesEst. completion Jan 31, 2030